STOCK TITAN

Prophase Labs Inc - PRPH STOCK NEWS

Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.

Company Overview

ProPhase Labs Inc (symbol: PRPH) is a diversified medical science and natural health company focused on advancing diagnostic testing, genomics, and contract manufacturing solutions. Integrating advanced AI platforms and expansive genomics databases, the company offers diagnostic services and consumer products that leverage deep scientific insights to support healthcare innovation, diagnostics, and biotechnology applications.

Business Segments

The company operates through two primary business segments:

  • Diagnostic Services: This segment provides a range of diagnostic testing services including COVID-19 diagnostic information paired with comprehensive testing solutions used by health plans, third-party payers, and government organizations.
  • Consumer Products: Focused on research, development, manufacturing, and sale of OTC consumer healthcare products and dietary supplements, this segment also includes personal genomics products and testing services aimed at empowering individuals with health-focused information.

Core Competencies and Market Position

ProPhase Labs distinguishes itself in the competitive healthcare and biotechnology sectors by leveraging its advanced artificial intelligence capabilities and patented insights, particularly in developing innovative solutions such as antibody drug conjugates. Its strategic approach to integrating diagnostic testing with personal genomics and consumer health solutions positions the company as a multifaceted player in a continuously evolving market.

Technological Innovation and Industry Impact

With a robust genomics database and a platform that utilizes AI for deep data analysis, ProPhase Labs underscores its commitment to scientific research and technological advancement. This innovative model not only enhances its diagnostic accuracy but also fuels the development of breakthrough products in oncology and medical diagnostics. By using industry-specific technological methodologies, the company demonstrates its expertise in enhancing diagnostic testing and consumer health product development.

Operational Excellence and Strategic Focus

Operating in a landscape where precision and reliable data are critical, ProPhase Labs ensures that its services are designed to meet the rigors of both clinical and consumer environments. The company's dual approach—addressing both institutional needs through its diagnostic services and individual consumer requirements via its healthcare products—illustrates its comprehensive market strategy. The clear delineation between these segments helps maintain operational focus and strategic clarity, positioning it as a trusted entity among healthcare professionals and consumers alike.

Research, Development, and Contract Manufacturing

Beyond its direct testing and consumer services, ProPhase Labs also engages in extensive research and development activities. Its contract manufacturing capabilities allow for the dedicated production of healthcare products and innovative diagnostic tests. This integrated business model supports continuous improvement in product quality while meeting the diverse needs of its clientele and staying ahead in a competitive industry.

Expertise, Experience, and Trust

By combining scientific expertise with practical experience in both diagnostics and consumer health products, ProPhase Labs commits to delivering reliable and cutting-edge solutions. Its operation underscores a balanced blend of clinical application and consumer accessibility, fostering a reputation built on trust, meticulous research, and technological innovation. The company’s methodical approach to integrating advanced diagnostics with personalized health monitoring has earned its recognition in the complex interplay of healthcare and genomics innovation.

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces positive preliminary results for Equivir dietary supplement trial, showing potential to reduce upper respiratory illnesses. Second trial completion expected in Q2 2024, with plans for commercialization and product launch in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
Rhea-AI Summary
Sidus Space (NASDAQ: SIDU) has announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White brings over 30 years of experience in financial management, operations, and business development. He has previously served as CFO of ProPhase Labs, Inc. and Intellicheck, Inc. Teresa Burchfield will step down as CFO after two years with the Company but will remain in an advisory role to assist with the transition. The CEO expressed gratitude for Burchfield's contributions and looks forward to the future growth and value creation under White's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
management
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces that Jason Karkus, known for his success in the Covid testing space, becomes President of Nebula Genomics, a subsidiary of ProPhase. Karkus will focus on expanding the business-to-business operations and direct-to-consumer Whole Genome Sequencing (WGS) model. ProPhase's WGS lab, equipped with cutting-edge sequencing platforms, aims to revolutionize the genomics industry. The company's strategic move from Covid testing to advanced WGS is expected to drive growth and shareholder returns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary. PMI has won two new contracts in January, projecting a significant increase in revenues and profitability. The company is in late-stage discussions with two additional large global brands, aiming to triple run-rate of revenues before year-end 2024. PMI has implemented price increases across its product line, acquired automation equipment, and signed deals with top-tier lozenge brands, projecting to inject an additional $5 million in annual revenue and more than $1.25 million in additional yearly pre-tax net profits. The company also plans to double capacity by Q2 2024 and further increase annual production capabilities to a range of $60-$80 million by Q4 2024. The CEO envisions scaling the business to a potential $80-$100 million production capacity with healthy net profit margins by the next 18-24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces the hiring of Jed Latkin as COO to help develop and grow its subsidiaries, including the commercialization of the BE-SMART esophageal cancer test in 2024. Mr. Latkin, a long-time industry veteran with a Columbia MBA, has been awarded a stock option to purchase up to 500,000 shares of the Company's common stock as an inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a successful transition to development stage, growth-oriented subsidiaries, with significant upside growth potential. The company aims for liquidity events in one or more subsidiaries in 2024 at implied valuations that may exceed the entire current market cap. Pharmaloz Manufacturing is on track to increase capacity from $10 million to over $75 million in 2024, with indications of demand for entire planned expansion. Nebula Genomics opens a new Whole Genome Sequencing lab in NY and sees significant demand. The company anticipates generating significant net profits by the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
Rhea-AI Summary
ProPhase Labs, Inc. will hold a conference call on November 9, 2023, to discuss its third-quarter results and provide a business update. The call will be hosted by CEO Ted Karkus. Participants can register for the call online or dial in. The call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences earnings
-
Rhea-AI Summary
ProPhase Labs unveils expansion strategy for its subsidiary, Pharmaloz Manufacturing, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
Rhea-AI Summary
ProPhase Labs to present at The ThinkEquity Conference on October 19, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences

FAQ

What is the current stock price of Prophase Labs (PRPH)?

The current stock price of Prophase Labs (PRPH) is $0.3513 as of April 22, 2025.

What is the market cap of Prophase Labs (PRPH)?

The market cap of Prophase Labs (PRPH) is approximately 7.6M.

What are the main business segments of ProPhase Labs Inc?

The company operates primarily in diagnostic services and consumer products. The diagnostic segment offers testing and genomic services, while the consumer segment focuses on OTC healthcare products and dietary supplements.

How does ProPhase Labs generate revenue?

ProPhase Labs generates revenue through its dual-business model, offering diagnostic testing services to institutions and consumer products to individual markets, including personal genomics solutions.

What role does technology play in ProPhase Labs' operations?

Technology is central to their operations. The company leverages advanced AI, expansive genomics databases, and innovative testing methodologies to enhance diagnostic accuracy and product development.

How does the company differentiate itself in the competitive healthcare market?

ProPhase Labs differentiates itself by integrating advanced scientific research with practical diagnostic and consumer health solutions. Their focus on personalized genomics and AI-driven analysis sets them apart from standard industry practices.

What are the core competencies of ProPhase Labs?

The company excels in diagnostic testing, genomics analysis, and contract manufacturing within the healthcare and biotechnology sectors, underscoring a blend of technical proficiency and innovative product development.

Who are the primary customers of ProPhase Labs?

The customer base is diverse, ranging from health plans, government agencies, and third-party payers for diagnostic services to individual consumers seeking OTC healthcare products and personal genomics insights.
Prophase Labs Inc

Nasdaq:PRPH

PRPH Rankings

PRPH Stock Data

7.64M
38.55M
11.16%
8.63%
5.49%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States
NEW YORK